Advances in immunotherapy for human epidermal growth factor receptor 2-positive breast cancer / 中华微生物学和免疫学杂志
Chinese Journal of Microbiology and Immunology
;
(12): 642-646, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-958237
ABSTRACT
Human epidermal growth factor receptor 2 (HER2)-targeted therapy has greatly improved the prognosis of HER2-positive breast cancer. HER2-targeted therapy combined with chemotherapy dominated by trastuzumab+ pertuzumab is important in the neoadjuvant therapy, postoperative adjuvant therapy and late-stage standard treatment for HER2-positive breast cancer. Antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) have further improved the efficacy of therapy. However, advanced breast cancer will eventually get a recurrence or drug resistance. HER2-positive breast cancer is characterized by moderate immunogenicity with the presence of large tumor-infiltrating lymphocytes (TILs), which provides a theoretical basis for immunotherapy. The application of HER2-targeted cancer vaccines and immune checkpoint inhibitors is promising and would offer more treatment options for the patients.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Microbiology and Immunology
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS